|CEO of Johnson & Johnson|
Assumed office |
|Preceded by||William C. Weldon|
|Born||May 24, 1960|
|Residence||New York City, New York|
West Point |
Wharton School of the University of Pennsylvania
US$ 847,692 (2012)|
Total: US$ 6,836,860 (2012)
Alex Gorsky is an American businessman. He has been the Chief Executive Officer of Johnson & Johnson since April 26, 2012. On July 29, 2014, IBM selected him as one of the board of directors for the company.
Alex Gorsky graduated in 1982 with a Bachelor of Science from the U.S. Military Academy at West Point, New York. He spent six years in the United States Army, finishing his career with the rank of captain and earning the Ranger tab and Airborne wings. He served in Europe, the United States, and Panama. In 1996, he obtained a master's in business administration from the Wharton School of the University of Pennsylvania.
He spent eight years (having started in 1988) in various sales, marketing, and management roles at Janssen Pharmaceutica, a Johnson & Johnson unit based in New Jersey. He joined Novartis Pharmaceuticals Corporation in 2004 as Chief Operating Officer and Head of General Medicines.
He was appointed Head of Pharma North America and Chief Executive Officer of Novartis in fall 2005. He oversaw the growth of its cardiovascular franchise, which included products Diovan and Lotrel, and the launch of Enablex, a product for overactive bladder. He was also involved in the launch of Focalin XR for ADHD. During his tenure, he developed Novartis' Medicare strategy and created several Novartis awards.
He rejoined Johnson & Johnson, where he served as the worldwide chairman of the surgical care group at Johnson & Johnson and as the chairman of the company's pharmaceutical business in Europe, the Middle East and Africa. He was the worldwide chairman of the medical devices and diagnostics group at Johnson & Johnson, serving in that role until September 2009. He now serves as CEO.
Gorsky managed the marketing of Risperdal while at Johnson & Johnson using a strategy that downplayed the drug's side-effects, encouraged off-label use, and provided kickback payments to Omnicare, a company which provided drug services to nursing homes. Ultimately the fines for this conduct cost Johnson & Johnson $2.2 billion.
- "Johnson & Johnson Executive Profile". Business Week.
- "Johnson & Johnson - Investor Relations - Management Team". Investor.jnj.com. 2012-04-26. Retrieved 2012-08-13.
- "IBM Elects Two New Members to Its Board of Directors". marketwatch. Retrieved 29 July 2014.
- Armstrong, Drew; Langreth, Robert (2012-02-22). "J&J Names Alex Gorsky CEO to Replace William Weldon". bloomberg.com. Bloomberg Businessweek. Retrieved 22 May 2013.
- "Alex Gorsky-10 Fortune 500 military CEOs". CNN Money. Retrieved 22 May 2013.
- Alex Gorsky. "Alex Gorsky: Executive Profile & Biography - Businessweek". Investing.businessweek.com. Retrieved 2012-08-13.
- "Stock Quotes & Company News". Reuters.com. Retrieved 2012-08-13.
- "Alex Gorsky, MBA". Stanford University. Retrieved 22 May 2013.
- "Biography of Alex Gorsky : The Wharton Global Alumni Forum-Zürich". Whartonzurich07.com. Retrieved 2012-08-13.
- "When Crime Pays: J&J's Drug Risperdal". nytimes.com. Retrieved 2015-09-16.
- "Johnson & Johnson to Pay More Than $2.2 Billion to Resolve Criminal and Civil Investigations". justice.gov. United States Department of Justice. 2013-11-04. Retrieved 2015-09-16.